Regeneron Drug maker announced plans Monday to begin Phase 3 clinical trials of a "double antibody cocktail" for use as a possible treatment for COVID-19.
The Phase 3 trial, the last stage of evaluation in the drug approval process, will assess the ability of the cocktail, called REGN-COV2, to prevent infection among uninfected people who have had "close exposure" to someone with COVID-19, company officials said.COVID-19 is the disease caused by the new coronavirus, SARS-CoV-2.
"We are running simultaneous adaptive trials in order to move as quickly as possible to provide a potential solution to prevent and treat COVID-19 infections, even in the midst of an ongoing global pandemic," Dr. George D. Yancopoulos, Regeneron's co-founder, president and chief scientific officer, said in a statement yesterday.

click to continue reading...........https://qwertywap.com/phase-3-trials-of-antibody-cocktail-for-covid-19-regeneron-to-launch/23943/